Difference between revisions of "SMARCA4-deficient non-small cell carcinoma of the lung"
Jump to navigation
Jump to search
(→IHC) |
|||
| Line 14: | Line 14: | ||
Note: | Note: | ||
*Hepatoid [[adenocarcinoma of lung]] shows cytoplasmic [[TTF-1]] staining.<ref name=pmid24030743>{{Cite journal | last1 = Haninger | first1 = DM. | last2 = Kloecker | first2 = GH. | last3 = Bousamra Ii | first3 = M. | last4 = Nowacki | first4 = MR. | last5 = Slone | first5 = SP. | title = Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature. | journal = Mod Pathol | volume = 27 | issue = 4 | pages = 535-42 | month = Apr | year = 2014 | doi = 10.1038/modpathol.2013.170 | PMID = 24030743 }}</ref> | *Hepatoid [[adenocarcinoma of lung]] shows cytoplasmic [[TTF-1]] staining.<ref name=pmid24030743>{{Cite journal | last1 = Haninger | first1 = DM. | last2 = Kloecker | first2 = GH. | last3 = Bousamra Ii | first3 = M. | last4 = Nowacki | first4 = MR. | last5 = Slone | first5 = SP. | title = Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature. | journal = Mod Pathol | volume = 27 | issue = 4 | pages = 535-42 | month = Apr | year = 2014 | doi = 10.1038/modpathol.2013.170 | PMID = 24030743 }}</ref> | ||
==Sign out== | |||
<pre> | |||
The tumour stains as follows: | |||
POSITIVE: CK7 (diffuse, strong), HepPar-1 (strong, diffuse). | |||
NEGATIVE: TTF-1, napsin A, p63, CK5/6. | |||
The staining pattern for this tumour is not typical for lung adenocarcinoma; please correlate with the clinical findings. | |||
HepPar-1 POSITIVITY with CK7 POSITIVITY and TTF-1 NEGATIVITY may be seen in SMARCA4-deficient adenocarcinoma of the lung.[1] | |||
1. Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282. | |||
</pre> | |||
==See also== | ==See also== | ||
Revision as of 19:18, 24 October 2019
SMARCA4-deficient non-small cell carcinoma of the lung is an emerging subtype of lung cancer.[1]
General
- ~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.[2]
- May represent or overlap with what is known as hepatoid adenocarcinoma of the lung.[citation needed]
IHC
Features:[1]
- CK7 +ve.
- TTF-1 -ve.
- HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).[1]
- SMARCA4 -ve.
Note:
- Hepatoid adenocarcinoma of lung shows cytoplasmic TTF-1 staining.[3]
Sign out
The tumour stains as follows: POSITIVE: CK7 (diffuse, strong), HepPar-1 (strong, diffuse). NEGATIVE: TTF-1, napsin A, p63, CK5/6. The staining pattern for this tumour is not typical for lung adenocarcinoma; please correlate with the clinical findings. HepPar-1 POSITIVITY with CK7 POSITIVITY and TTF-1 NEGATIVITY may be seen in SMARCA4-deficient adenocarcinoma of the lung.[1] 1. Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282.
See also
References
- ↑ 1.0 1.1 1.2 Agaimy, A.; Fuchs, F.; Moskalev, EA.; Sirbu, H.; Hartmann, A.; Haller, F. (Nov 2017). "SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1". Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282.
- ↑ Herpel, E.; Rieker, RJ.; Dienemann, H.; Muley, T.; Meister, M.; Hartmann, A.; Warth, A.; Agaimy, A. (Feb 2017). "SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.". Ann Diagn Pathol 26: 47-51. doi:10.1016/j.anndiagpath.2016.10.006. PMID 28038711.
- ↑ Haninger, DM.; Kloecker, GH.; Bousamra Ii, M.; Nowacki, MR.; Slone, SP. (Apr 2014). "Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature.". Mod Pathol 27 (4): 535-42. doi:10.1038/modpathol.2013.170. PMID 24030743.